tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Entrada Therapeutics reports Q3 EPS ($1.06), consensus (96c)
PremiumThe FlyEntrada Therapeutics reports Q3 EPS ($1.06), consensus (96c)
3d ago
Entrada Therapeutics: Undervalued Leader in RNA Therapeutics with Promising DMD Pipeline
Premium
Ratings
Entrada Therapeutics: Undervalued Leader in RNA Therapeutics with Promising DMD Pipeline
12d ago
3 Best Stocks to Buy Now, 10/24/2025, According to Top Analysts
Premium
Market News
3 Best Stocks to Buy Now, 10/24/2025, According to Top Analysts
16d ago
Promising Clinical Developments and Strategic Pipeline Expansion Support Buy Rating for Entrada Therapeutics
PremiumRatingsPromising Clinical Developments and Strategic Pipeline Expansion Support Buy Rating for Entrada Therapeutics
3M ago
Entrada Therapeutics reports Q2 EPS ($1.04), consensus (86c)
Premium
The Fly
Entrada Therapeutics reports Q2 EPS ($1.04), consensus (86c)
3M ago
Entrada Therapeutics Holds Virtual Annual Stockholders Meeting
Premium
Company Announcements
Entrada Therapeutics Holds Virtual Annual Stockholders Meeting
5M ago
Entrada Therapeutics price target lowered to $21 from $23 at Roth Capital
PremiumThe FlyEntrada Therapeutics price target lowered to $21 from $23 at Roth Capital
6M ago
Entrada Therapeutics price target lowered to $21 from $23 at Roth Capital
Premium
The Fly
Entrada Therapeutics price target lowered to $21 from $23 at Roth Capital
6M ago
Entrada Therapeutics: Strategic Advancements in DMD Pipeline Drive Buy Rating
Premium
Ratings
Entrada Therapeutics: Strategic Advancements in DMD Pipeline Drive Buy Rating
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100